Hepatitis: HCV variability, the immune system and resistance to antiviral drugs

Nature Reviews Gastroenterology and Hepatology

Volumn 6, Issue 7, 2009, Pages 383-385

  Pawlotsky, Jean Michel ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; CYCLOPHILIN INHIBITOR; NONSTRUCTURAL PROTEIN 3 INHIBITOR; NONSTRUCTURAL PROTEIN 4A INHIBITOR; NONSTRUCTURAL PROTEIN 5A INHIBITOR; PEGINTERFERON ALPHA; PROTEINASE INHIBITOR; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; RNA DIRECTED RNA POLYMERASE; TELAPREVIR; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; DRUG EFFICACY; GENETIC VARIABILITY; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS; HLA TYPING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNE SYSTEM; LONG TERM CARE; NONHUMAN; PRIORITY JOURNAL; SEQUENCE ANALYSIS; VIRUS INHIBITION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; DRUG DESIGN; DRUG RESISTANCE, VIRAL; HEPATITIS C, CHRONIC; HUMANS;

EID: 67650866272     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2009.102     Document Type: Article

References (14)

1. Pawlotsky, J. M. Hepatitis C virus population dynamics during infection. Curr. Top. Microbiol. Immunol. 299, 261-284 (2006).
2. Clavel, F. & Hance, A. J. Hiv drug resistance. N. Engl. J. Med. 350, 1023-1035 (2004).
3. Pawlotsky, J. M., Chevaliez, S. & McHutchison, J. G. The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology 132, 1979-1998 (2007).
4. Sarrazin, C. et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 132, 1767-1777 (2007).
5. Migliaccio, G. et al. Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro. J. Biol. Chem. 278, 49164-49170 (2003).
6. Dutartre, H., Bussetta, C., Boretto, J. & Canard, B. General catalytic deficiency of hepatitis C virus RnA polymerase with an S282T mutation and mutually exclusive resistance towards 2′-modified nucleotide analogues. Antimicrob. Agents Chemother. 50, 4161-4169 (2006).
7. Coelmont, L. et al. Particular in vitro anti-HCV activities and resistance profile of the cyclophilin inhibitor DEBiO-025. J. Hepatol. 50 (suppl. 1), s36 (2009).
8. Gaudieri, S. et al. Hepatitis C virus drug resistance and immune-driven adaptations: Relevance to new antiviral therapy. Hepatology 49, 1069-1082 (2009).
9. Foster, G. R. et al. Activity of telaprevir alone or in combination with peginterferon alfa-2a and ribavirin in treatment-naive genotype 2 and 3 hepatitis C patients: Interim results of study C209. J. Hepatol. 50 (suppl. 1), s22 (2009).
10. Lawitz, E. et al. Antiviral activity of ANA598, a potent non-nucleoside polymerase inhibitor, in chronic hepatitis C patients. J. Hepatol. 50 (suppl. 1), s384 (2009).
11. McCown, M. F., Rajyaguru, S., Kular, S., Cammack, N. & Najera, I. GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCv-796. Antimicrob. Agents Chemother. 53, 2129-2132 (2009).
12. Kuntzen, T. et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology 48, 1769-1778 (2008).
13. Bartels, D. J. et al. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3/4A protease inhibitors in treatment-naive subjects. J. Infect. Dis. 198, 800-807 (2008).
14. Hezode, C. et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N. Engl. J. Med. 360, 1839-1850 (2009).